Associated Papers
Current advances in the clinical management of Perry syndrome: is there hope for the future?
Chmiela T et al.
Expert Review of Neurotherapeutics, 2026
A systematic review and functional in-silico analysis of genes and variants associated with amyotrophic lateral sclerosis.
Arreola-Aldape CA et al.
Frontiers in Neuroscience, 2025
First family with Perry syndrome from Mexico.
Flores-Lagunes L et al.
Biomedical Reports, 2024
Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
Saffie Awad P et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2024
Wild-Type DCTN1 Suppresses the Aggregation of DCTN1 Mutants Associated with Perry Disease.
Fukui Y et al.
Biological & Pharmaceutical Bulletin, 2024
Perry syndrome: Novel DCTN1 mutation in a large kindred and first observation of prodromal disease.
Dulski J et al.
Parkinsonism & Related Disorders, 2023
Perry Disease: Expanding the Genetic Basis.
Dulski J et al.
Movement Disorders Clinical Practice, 2023
Deficiency of Perry syndrome-associated p150Glued in midbrain dopaminergic neurons leads to progressive neurodegeneration and endoplasmic reticulum abnormalities.
Yu J et al.
Npj Parkinson's Disease, 2023
Perry disease in an Argentine family due to the DCTN1 p.G67D variant.
Silva E et al.
Parkinsonism & Related Disorders, 2022
Selective expression of neurodegenerative diseases-related mutant p150Glued in midbrain dopaminergic neurons causes progressive degeneration of nigrostriatal pathway.
Yu J et al.
Ageing and Neurodegenerative Diseases, 2022
Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review.
Dulski J et al.
European Journal of Neurology, 2021
Meta-iodobenzylguanidine myocardial scintigraphy in Perry disease.
Mishima T et al.
Parkinsonism & Related Disorders, 2021
Perry Disease: Concept of a New Disease and Clinical Diagnostic Criteria.
Tsuboi Y et al.
Journal of Movement Disorders, 2021
Novel destabilizing Dynactin variant (DCTN1 p.Tyr78His) in patient with Perry syndrome.
Čierny M et al.
Parkinsonism & Related Disorders, 2020
Perry syndrome: a case of atypical parkinsonism with confirmed DCTN1 mutation: a response.
Tacik P et al.
The New Zealand Medical Journal, 2020
Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells.
Mishima T et al.
International Journal of Molecular Sciences, 2018
DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy.
Honda H et al.
Parkinsonism & Related Disorders, 2018
Establishing diagnostic criteria for Perry syndrome.
Mishima T et al.
Journal of Neurology, Neurosurgery, and Psychiatry, 2018
Behavioral defects in a DCTN1G71A transgenic mouse model of Perry syndrome.
Mishima T et al.
Neuroscience Letters, 2018
Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy.
Mishima T et al.
Parkinsonism & Related Disorders, 2017
DCTN1-related neurodegeneration: Perry syndrome and beyond.
Konno T et al.
Parkinsonism & Related Disorders, 2017
Cytoplasmic aggregates of dynactin in iPSC-derived tyrosine hydroxylase-positive neurons from a patient with Perry syndrome.
Mishima T et al.
Parkinsonism & Related Disorders, 2016
DCTN1 p.K56R in progressive supranuclear palsy.
Gustavsson EK et al.
Parkinsonism & Related Disorders, 2016
Three families with Perry syndrome from distinct parts of the world.
Tacik P et al.
Parkinsonism & Related Disorders, 2014
Expansion of the clinicopathological and mutational spectrum of Perry syndrome.
Chung EJ et al.
Parkinsonism & Related Disorders, 2014
Perry syndrome: a disorder to consider in the differential diagnosis of Parkinsonism.
Aji BM et al.
Journal of the Neurological Sciences, 2013
[A case of brugada syndrome presenting with syncope transferred by ambulance to a neurosurgical hospital].
Sawamura A et al.
No Shinkei Geka. Neurological Surgery, 2010